NASDAQ NMS - GLOBAL MARKET · KOD
+1.00% · +$0.3600 · Vol 611.4K
Kodiak Sciences Inc

Kodiak Sciences Inc

Biotechnology
$36.50

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is KOD moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Kodiak Sciences Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2018
Employees
124
Country
US

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$36.99
Day high
$38.08
Day low
$36.40
Previous close
$36.14
52W high
$38.08
-4.14% from high
52W low
$31.41
76% of range
Market cap
$2.3B
EPS
$-4.0300
Shares out
62.6M
Volume
611.4K
VWAP
$37.02
Price history computed in-house
1W
+2.53%
SMA 50 $34.63 · above
SMA 200 $34.63 · above
52W position 76%
Veridion warehouse edge

Warehouse intelligence for KOD.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

KOD insider activity

Kodiak Sciences Inc

Score
Coverage building
Pressure
Net buying
Filings
12
Buys / sells
6 / 6
Net value
$58.2M
Insiders
3
Named filers
BA
BORGESON JOHN A.
Insider
Leadership
PV
PERLROTH VICTOR
Insider
Leadership
BJ
BAKER JULIAN
Insider
Leadership
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net buying: $58.2M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-06-052026-06-04BORGESON JOHN A.Insidersell$34.674,104211,930$142KSEC Form 4
2026-06-052026-06-04BORGESON JOHN A.Insidersell$34.0125,896216,034$881KSEC Form 4
2026-06-052026-06-04BORGESON JOHN A.Insiderbuy$1.0430,000241,930$31KSEC Form 4
2026-04-162026-04-15BORGESON JOHN A.Insiderbuy$1.0428,614211,930$30KSEC Form 4
2026-04-022026-04-02BORGESON JOHN A.Insidersell$41.77600183,316$25KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 7 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

KOD contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KOD in this window.
Lobbying spend

KOD lobbying filings, year to date.

Registered lobbying filings matched to Kodiak Sciences Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KOD in this window.
Latest news · KOD
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for KOD.
Options
Sovereign unlock shows live options positioning for KOD.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.